Metagenomi Therapeutics, Inc. Diluted Shares Outstanding (Weighted Average)
Metagenomi Therapeutics, Inc. (MGX) reported Diluted Shares Outstanding (Weighted Average) of 37.66 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-10
- Metagenomi Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 37.66M shares, a 1.35% increase year-over-year.
- Metagenomi Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 37.58M shares, a 1.52% increase year-over-year.
- Metagenomi Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 37.48M shares, a 0.45% increase year-over-year.
- Metagenomi Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 37.35M shares, a 1.59% increase year-over-year.
- Metagenomi Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2025 was 37.25M shares, a 12.79% increase from fiscal 2024.
- Metagenomi Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2024 was 33.03M shares, a 870.10% increase from fiscal 2023.
- Metagenomi Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2023 was 3.40M shares.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 37.66M shares 10-Q · filed 2026-08-10 | 37.62M shares 10-Q · filed 2026-08-10 | 37.57M shares derived: average of 3 quarters · filed 2026-08-10 | 37.52M shares derived: average of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | 37.58M shares 10-Q · filed 2026-05-11 | 37.53M shares derived: average of 2 quarters · filed 2026-05-11 | 37.47M shares derived: average of 3 quarters · filed 2026-05-11 | 37.39M shares derived: average of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | 37.48M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 37.41M shares derived: average of 2 quarters · filed 2026-03-05 | 37.33M shares derived: average of 3 quarters · filed 2026-08-10 | 37.25M shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 37.35M shares 10-Q · filed 2025-11-12 | 37.25M shares derived: average of 2 quarters · filed 2026-08-10 | 37.18M shares 10-Q · filed 2025-11-12 | 37.21M shares derived: average of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | 37.16M shares 10-Q · filed 2026-08-10 | 37.09M shares 10-Q · filed 2026-08-10 | 37.16M shares derived: average of 3 quarters · filed 2026-08-10 | 37.06M shares derived: average of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | 37.02M shares 10-Q · filed 2026-05-11 | 37.16M shares derived: average of 2 quarters · filed 2026-05-11 | 37.03M shares derived: average of 3 quarters · filed 2026-05-11 | 36.93M shares derived: average of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | 37.31M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 37.04M shares derived: average of 2 quarters · filed 2026-03-05 | 36.90M shares derived: average of 3 quarters · filed 2026-03-05 | 33.03M shares 10-K · filed 2026-03-05 |
| 2024-09-30 | 36.77M shares 10-Q · filed 2025-11-12 | 36.70M shares derived: average of 2 quarters · filed 2025-11-12 | 31.60M shares 10-Q · filed 2025-11-12 | 24.48M shares derived: average of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | 36.63M shares 10-Q · filed 2025-08-12 | 28.90M shares 10-Q · filed 2025-08-12 | 20.39M shares derived: average of 3 quarters · filed 2025-08-12 | 16.14M shares derived: average of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | 21.14M shares 10-Q · filed 2025-05-13 | 12.27M shares derived: average of 2 quarters · filed 2025-05-13 | 9.32M shares derived: average of 3 quarters · filed 2025-05-13 | 7.84M shares derived: average of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | 3.40M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | 3.40M shares derived: average of 2 quarters · filed 2025-03-17 | 3.40M shares derived: average of 3 quarters · filed 2025-03-17 | 3.40M shares 10-K · filed 2025-03-17 |
| 2023-09-30 | 3.40M shares 10-Q · filed 2024-11-13 | 3.40M shares derived: average of 2 quarters · filed 2024-11-13 | 3.40M shares 10-Q · filed 2024-11-13 | |
| 2023-06-30 | 3.40M shares 10-Q · filed 2024-08-14 | 3.40M shares 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | 3.40M shares 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |